在复发性和/或转移性头颈部癌患者中每两个月使用西妥昔单抗的理由和预算影响。
Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer.
机构信息
Economic Evaluation and HTA (CEIS-EEHTA) - Faculty of Economics, University of Rome "Tor Vergata", Rome, Italy.
Department of Accounting, Finance and Informatics, Institute for Leadership and Management in Health - Kingston University London, London, United Kingdom.
出版信息
Head Neck. 2019 Apr;41(4):908-914. doi: 10.1002/hed.25481. Epub 2019 Jan 24.
BACKGROUND
In recurrent and/or metastatic head and neck squamous cell cancer, Cetuximab is administered once a week, followed by weekly doses. We present the clinical rationale of a different schedule of maintenance Cetuximab and we estimate the potential economic benefits on the health care budget from a societal perspective in Italy.
METHODS
A budget impact (BI) excel-based model was developed comparing a base case scenario of 100% weekly administration with a dose of 250 mg/m to an every-other-week (EOW) administration at 50% or 100% with a dose of 500 mg/m .
RESULTS
In the EOW, 50% scenario it was calculated a cost reduction of €347 000 of which 70% attributable to indirect costs, increasing to €694 000 after 4 months.
CONCLUSIONS
In our analysis, we showed that this simplified schedule could also reduce the costs of treatments both for the health system (direct costs) and for the society (indirect costs).
背景
在复发性和/或转移性头颈部鳞状细胞癌中，西妥昔单抗每周给药一次，随后每周给药。我们提出了维持西妥昔单抗不同方案的临床原理，并从意大利社会角度估计了对医疗保健预算的潜在经济效益。
方法
使用基于 Excel 的预算影响 (BI) 模型，我们将每周 100%给药方案（剂量为 250mg/m）与每两周（EOW）50%或 100%给药方案（剂量为 500mg/m）进行比较。
结果
在 EOW，50%的情况下，我们计算出成本降低了 347000 欧元，其中 70%归因于间接成本，4 个月后增加到 694000 欧元。
结论
在我们的分析中，我们表明这种简化的方案还可以降低医疗系统（直接成本）和社会（间接成本）的治疗成本。
Zotero 插件